Congress' Year-End Appropriations Package Brings FDA Legislative Changes, Leaves Unresolved Policy Issues - Life Sciences, Biotechnology & Nanotechnology
In a break with past precedent, last year's Food and Drug Administration (FDA) user fee reauthorization legislation did not contain significant FDA policy changes.
United States Device Manufacturer Communications With Payors Exchange Of Product Information Prior To Approval Pharmaceuticals For Children Office Of Critical Foods Public Health Service
Source: mondaq.com